



Press Release - 24. September 2025

Prevision Medicine Launches Breakthrough Glioblastoma Drug Screening Test

Glioblastoma (GBM) is the most **common and aggressive form of primary brain cancer in adults**. Prevision Medicine, a Swiss-based company and leader in functional precision medicine, today announced the clinical launch of its cutting-edge Glioblastoma Drug-Screening Test for research use only, powered by the company's proprietary PrevisionOne platform. **The test is designed to help oncologists rapidly identify the most effective therapies for patients affected by GBM.**

This milestone comes just a few weeks after the company's successful launch of its breakthrough drug screening test for Acute Myeloid Leukemia (AML), underscoring its ongoing progress in expanding precision oncology solutions.

"Glioblastoma is a highly malignant brain tumor thought to originate from stem cells of the normal brain. **Half of the patients die within one year of diagnosis, despite multimodality treatment of surgery, radiotherapy and chemotherapy**", says Prof. Dr. Micheal Weller, Director of the Department of Neurology at the University Hospital Zurich.





Developed in collaboration with the **University Hospital Zurich** and other leading hospitals in Switzerland, Prevision's GBM RUO test is based on evidence collected through an observational clinical study published in Nature Medicine last year ([*Link to the Study*](#)). The study demonstrated that image-based drug testing can **predict responses** to standard-of-care treatment options and **identify additional potential therapies**.

"Glioblastoma has long posed a major treatment challenge – its variability and the lack of standard therapies demand a precision-guided approach," says Philip Zimmermann, CEO, Prevision Medicine. "Our drug-screening test provides clinicians with functional data, empowering them to identify effective therapies quickly, and transforming how this devastating disease is managed."

"Novel treatment approaches to glioblastoma are urgently needed. Prevision's innovative approach of ex vivo drug sensitivity profiling offers **new hope for patients** afflicted by glioblastoma and for their caregivers."

Prof. Dr. Micheal Weller
Director of the Department of Neurology
University Hospital Zurich



Key Features of the GBM Drug Screening Test

Rooted in Pharmacoscopy – the clinically most validated functional precision medicine method which uses image-based single-cell data to evaluate ex vivo patient drug responses.

High-throughput functional test assessing patient cancer biopsy cell responses to an extensive panel of drugs and drug combinations designed to reach the brain.

First observational evidence to be predictive for the standard of care.

Tailored for rapid clinical adoption, with an average 72 hours turn-around time from sample reception to test report, empowering physicians with fast treatment decision options for their patients.

“Glioblastoma has long posed a major treatment challenge – its variability and the lack of standard therapies demand a precision-guided approach. Our drug-screening test **provides clinicians with functional data, empowering them to identify effective therapies quickly**, and transforming how this devastating disease is managed.”

Dr. Philip Zimmermann
CEO Prevision Medicine





About

Prevision Medicine is a Swiss-based company at the forefront of functional precision medicine, dedicated to reshaping cancer care through advanced, evidence-driven drug-screening technologies.

Its proprietary PrevisionOne platform delivers actionable insights to support data-driven, patient-specific treatment strategies across multiple cancer types, improving outcomes and quality of care.

For more information, please visit:

www.previsionmedicine.com

General and Business Inquiries

Valentin Matillon, Chief Business Officer

valentin@previsionmedicine.com

Media Inquiries

info@previsionmedicine.com

